NovoPen Echo® insulin delivery device

NovoPen Echo® insulin delivery device

Jacob Hyllested-Winge,1 Thomas Sparre,2 Line Kynemund Pedersen2 1Novo Nordisk Pharma Ltd, Tokyo, Japan; 2Novo Nordisk A/S, Søborg, Denmark Abstract: The introduction of insulin pen devices has provided easier, well-tolerated, and more convenient treatment regimens for patients with diabe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hyllested-Winge J, Sparre T, Pedersen LK
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
NovoPen Echo®
memory function
half-unit increment dosing
adherence
children
adolescents
Medical technology
R855-855.5
Acceso en línea:https://doaj.org/article/a75546e1dc284b9b9094eb3a17096903
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a75546e1dc284b9b9094eb3a17096903
record_format dspace
spelling oai:doaj.org-article:a75546e1dc284b9b9094eb3a170969032021-12-02T07:38:51ZNovoPen Echo® insulin delivery device1179-1470https://doaj.org/article/a75546e1dc284b9b9094eb3a170969032016-01-01T00:00:00Zhttps://www.dovepress.com/novopen-echoreg-insulin-delivery-device-peer-reviewed-article-MDERhttps://doaj.org/toc/1179-1470Jacob Hyllested-Winge,1 Thomas Sparre,2 Line Kynemund Pedersen2 1Novo Nordisk Pharma Ltd, Tokyo, Japan; 2Novo Nordisk A/S, Søborg, Denmark Abstract: The introduction of insulin pen devices has provided easier, well-tolerated, and more convenient treatment regimens for patients with diabetes mellitus. When compared with vial and syringe regimens, insulin pens offer a greater clinical efficacy, improved quality of life, and increased dosing accuracy, particularly at low doses. The portable and discreet nature of pen devices reduces the burden on the patient, facilitates adherence, and subsequently contributes to the improvement in glycemic control. NovoPen Echo® is one of the latest members of the NovoPen® family that has been specifically designed for the pediatric population and is the first to combine half-unit increment (=0.5 U of insulin) dosing with a simple memory function. The half-unit increment dosing amendments and accurate injection of 0.5 U of insulin are particularly beneficial for children (and insulin-sensitive adults/elders), who often require small insulin doses. The memory function can be used to record the time and amount of the last dose, reducing the fear of double dosing or missing a dose. The memory function also provides parents with extra confidence and security that their child is taking insulin at the correct doses and times. NovoPen Echo is a lightweight, durable insulin delivery pen; it is available in two different colors, which may help to distinguish between different types of insulin, providing more confidence for both users and caregivers. Studies have demonstrated a high level of patient satisfaction, with 80% of users preferring NovoPen Echo to other pediatric insulin pens. Keywords: NovoPen Echo®, memory function, half-unit increment dosing, adherence, children, adolescents Hyllested-Winge JSparre TPedersen LKDove Medical PressarticleNovoPen Echo®memory functionhalf-unit increment dosingadherencechildrenadolescentsMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2016, Iss Issue 1, Pp 11-18 (2016)
institution DOAJ
collection DOAJ
language EN
topic NovoPen Echo®
memory function
half-unit increment dosing
adherence
children
adolescents
Medical technology
R855-855.5
spellingShingle NovoPen Echo®
memory function
half-unit increment dosing
adherence
children
adolescents
Medical technology
R855-855.5
Hyllested-Winge J
Sparre T
Pedersen LK
NovoPen Echo® insulin delivery device
description Jacob Hyllested-Winge,1 Thomas Sparre,2 Line Kynemund Pedersen2 1Novo Nordisk Pharma Ltd, Tokyo, Japan; 2Novo Nordisk A/S, Søborg, Denmark Abstract: The introduction of insulin pen devices has provided easier, well-tolerated, and more convenient treatment regimens for patients with diabetes mellitus. When compared with vial and syringe regimens, insulin pens offer a greater clinical efficacy, improved quality of life, and increased dosing accuracy, particularly at low doses. The portable and discreet nature of pen devices reduces the burden on the patient, facilitates adherence, and subsequently contributes to the improvement in glycemic control. NovoPen Echo® is one of the latest members of the NovoPen® family that has been specifically designed for the pediatric population and is the first to combine half-unit increment (=0.5 U of insulin) dosing with a simple memory function. The half-unit increment dosing amendments and accurate injection of 0.5 U of insulin are particularly beneficial for children (and insulin-sensitive adults/elders), who often require small insulin doses. The memory function can be used to record the time and amount of the last dose, reducing the fear of double dosing or missing a dose. The memory function also provides parents with extra confidence and security that their child is taking insulin at the correct doses and times. NovoPen Echo is a lightweight, durable insulin delivery pen; it is available in two different colors, which may help to distinguish between different types of insulin, providing more confidence for both users and caregivers. Studies have demonstrated a high level of patient satisfaction, with 80% of users preferring NovoPen Echo to other pediatric insulin pens. Keywords: NovoPen Echo®, memory function, half-unit increment dosing, adherence, children, adolescents 
format article
author Hyllested-Winge J
Sparre T
Pedersen LK
author_facet Hyllested-Winge J
Sparre T
Pedersen LK
author_sort Hyllested-Winge J
title NovoPen Echo® insulin delivery device
title_short NovoPen Echo® insulin delivery device
title_full NovoPen Echo® insulin delivery device
title_fullStr NovoPen Echo® insulin delivery device
title_full_unstemmed NovoPen Echo® insulin delivery device
title_sort novopen echo® insulin delivery device
publisher Dove Medical Press
publishDate 2016
url https://doaj.org/article/a75546e1dc284b9b9094eb3a17096903
work_keys_str_mv AT hyllestedwingej novopenechoreginsulindeliverydevice
AT sparret novopenechoreginsulindeliverydevice
AT pedersenlk novopenechoreginsulindeliverydevice
_version_ 1718399300072898560

Ejemplares similares